ERBB2 and breast cancer: Beside advanced stage at diagnosis, young patients with BC had worse clinical outcomes, partly because of the over-representation of more aggressive subtypes such as TNBC or HER2+ BC.26 In fact, in our study, higher proportions of women with stage II and III BC and TNBC were younger than 40 years.